Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Completed · Phase 2, Phase 3 · NCT04315298
Conditions: COVID-19
At a glance
- Research payments reported, 2025
- $5,160
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1,912
About the trial
- Sponsor
- Regeneron Pharmaceuticals (with Sanofi)
- Tested
- Sarilumab (drug), Placebo (drug)
- Dates
- Started 2020-03-18; completion 2020-09-02
- Results posted
- Yes
Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata. Phase 3 Cohort 1: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with critical COVID-19 receiving mechanical ventilation at baseline. Phase 3 Cohort 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 receiving mechanical ventilation at baseline.
From ClinicalTrials.gov, last updated 2021-09-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $5,160 in research payments for this study in 2025 (2 payments).
Products named: Kevzara
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.